A Phase II Evaluation of Afatinibin Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma
Status:
Recruiting
Trial end date:
2028-07-01
Target enrollment:
Participant gender:
Summary
Primary Objective: To assess the activity of Afatinib in patients with persistent or
recurrent uterine serous carcinoma overexpressing HER2/neu with the frequency of patients who
survive progression-free for at least 6 months after initiating therapy. Secondary
Objectives: To assess objective response rate and durable disease control rate. To assess
overall survival. To assess the safety profile of Afatinib in uterine serous carcinoma
patients.